Radspherin

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence. In this Phase 1 trial, 10 out of 21 patients received the highest and recommended intraperitoneal dose of 7 MBq Radspherin® after dose escalation (1, 2, 4 and 7 MBq). The final 24-month data still reports that only 1 of these 10 patients had peritoneal recurrence, and peritoneal recurrence rate remains at 10%. Two additional patients were reported with lymph node metastases outside of the peritoneum, giving an overall recurrence rate of 30%. In similar populations, approximately 55-60% of patients receiving best standard of care would expect disease recurrence at this time point[1],[2],[3]. "These highly encouraging results conclude our Phase 1 program for Radspherin® and fuel our determination to advance Radspherin® as an innovative treatment for patients with peritoneal metastases as quickly as possible," said Oystein Soug, CEO of Oncoinvent. "We are profoundly grateful to the patients, investigators, and the team for their invaluable contributions and look forward to interim results from our Phase 2 study next year." "Peritoneal metastases remain a defining challenge in ovarian cancer, often driving recurrence," said Dr. Luis Chiva, Principal Investigator and Director of Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Spain. "These final results are truly encouraging, suggesting that Radspherin® could help delay disease progression and offer patients hope for longer, healthier lives. It is particularly promising to see that the new recurrences were limited to lymph nodes, which are typically associated with longer survival compared to peritoneal relapses. About RAD-18-001 RAD-18-001 was an open label Phase 1 trial conducted in patients with peritoneal metastases in platinum-sensitive recurrent ovarian cancer. The trial was designed to evaluate dosing, safety and tolerability, and signal of efficacy of intraperitoneally administered Radspherin® following complete surgical resection. A total of 21 patients were enrolled across sites in Norway, Belgium and Spain. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo. About Radspherin Radspherin® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of billions of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin® is investigated in clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally after surgical resection with removal of all macroscopic tumors. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. For further information, please contact: Oystein Soug, Chief Executive Officer Email: [email protected] Tore Kvam, Chief Financial Officer Email: [email protected] References: [1] Coleman et al. N Engl J Med. 2019 Nov 14;381(20):1929-1939 [2] Harter et al. N Engl J Med. 2021 Dec 2;385(23):2123-2131 [3] Shi et al. Lancet Oncol. 2021 Apr;22(4):439-449 This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Oslo-based Oncoinvent\'s lead radiopharma is in phase 2 trials.\n BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.The deal will see Oncoinvent’s shareholders own 75% of the merged company, with BerGenBio’s shareholders owning the remaining 25%. The resulting entity, which will operate under the Oncoinvent brand, will be focused on Oncoinvent’s lead radiopharma asset Radspherin.BerGenBio, which is based in Bergen, Norway, put its decision to go ahead with the merger in the context of the discontinuation in February of the biotech’s AXL kinase inhibitor bemcentinib. The company blamed a lack of responses in a phase 2 study of the lead candidate in non-small cell lung cancer and said at the time that it would now consider its strategic options—including a potential merger or sale.“This merger, which is backed by the boards of both companies, is the result of an extensive review that explored a range of strategic options for BerGenBio,” Anders Tullgren, chair of BerGenBio’s board, said in a June 30 postmarket release.“The merger gives BerGenBio shareholders a part of an exciting company leveraging Norwegian radiopharmaceutical technology, which has already seen encouraging preliminary efficacy data, without safety concerns,” Tullgren added. “We are confident that this is the best option for current BerGenBio shareholders.”The merger values BerGenBio at 65 million Norwegian kroner ($6.5 million) and Oncoinvent at 195.5 million kroner ($19.4 million).The deal will provide an additional 45 million kroner ($4.5 million) to fund Oncoinvent\'s clinical development plan, which is headed up by Radspherin, an alpha-emitting radionuclide radium-224 being tested in peritoneal cancer in patients who have had surgery for colorectal or ovarian cancers.Radspherin is currently being evaluated in a phase 2 trial across the U.S., UK and Europe with a readout penciled in for the second half of 2026. So far, preliminary efficacy data have been “highly encouraging,” Oncoinvent said in the release.The plan once the merger is completed is for a fully underwritten rights issue of 130 million kroner ($12.9 million), which should pave a cash runway past that readout and into 2027.“We are very excited for the time ahead and to continue the execution of our focused strategy to develop Radspherin in ovarian cancer,” Oncoinvent CEO Øystein Soug said in the release.“We are on track with our randomised phase 2 trial,” Soug added. “Going forward with a strengthened balance sheet, we believe the company will be a transformative force in the radiopharmaceutical therapy field, improving the lives of patients with cancer in the peritoneal cavity.”Oslo-based Oncoinvent was founded by Øyvind Bruland, M.D., Ph.D., and Roy Larsen, Ph.D., the pioneers behind Xofigo, a prostate cancer radiopharma drug that was acquired by Bayer in 2014 as part of its acquisition of Algeta.